Navigation Links
Synutra Announces Postponement of Proposed Offering
Date:7/18/2008

QINGDAO, China and ROCKVILLE, Md., July 18 /Xinhua-PRNewswire/ -- Synutra International, Inc. (Nasdaq: SYUT, "Synutra"), a leading infant formula company in China, and a producer, marketer and seller of nutritional products for infants, children and adults, announced today that it has postponed its proposed public offering of its common stock indefinitely.

"Due to current stock market conditions, our board has determined it is in the best interest of our stockholders to postpone the offering," said Liang Zhang, Chairman and CEO of Synutra International, Inc.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. A copy of the registration statement for this offering may be obtained at http://www.sec.gov . These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

About Synutra International, Inc.

Synutra, through its operating subsidiaries in China, is principally engaged in the development, production, distribution and sales of dairy-based nutritional products across the People's Republic of China. It offers its products for infants, children, adults, pregnant women and nursing mothers under the "Sheng Yuan" or "Synutra" master brand and several sub-brands, including "Super," "U-Smart" and "U-Strong." For more information, please contact Weiguo Zhang of Synutra, Inc. (301 840 3888, wzhang@synutra.com), Brian Rafferty of Taylor Rafferty (212 889 4350, synutra@taylor-rafferty.com) or visit: http://www.synutra.com .

The information contained herein includes statements, estimates, projections, guidance or outlook that constitute "forward-looking" statements as defined under U.S. federal securities laws. Generally the words "believe," "expect," "intend," "estimate," "anti
'/>"/>

SOURCE Synutra International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... VIENNA , Sept. 17, 2014 ... compelling, quantitative data from a study of the cost ... at the 50 th Annual Meeting of the ... a poster session today, Christian Frois , Ph.D., ... in a series of planned Intarcia-sponsored, retrospective studies to ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... 17 de septiembre de 2014  Cryoport, ... proveedor mundial de soluciones logísticas avanzadas criogénicas ... la vida, anunció hoy la contratación de ... con sede en Rótterdam, Países Bajos, para ... Europa en rápido crecimiento. Según los términos ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... the Nobel Prize shows a cat resting in a ... around graphene, which, at one atom thick, is the ... A significant obstacle to realizing graphene,s potential lies in ... sleeping cat. For now, material scientists stitch individual graphene ...
... Professor Federico Rosei of the INRS Energy Materials ... the prestigious 2010 Friedrich Wilhelm Bessel Research Award given ... 25 of these awards annually to young, high level ... recognition of the caliber and scope of his research ...
... ... ... ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
Cached Biology Technology:Graphene's strength lies in its defects 2INRS professor Federico Rosei receives a 2010 Friedrich Wilhelm Bessel Research Award 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 9YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 10YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 11YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 12YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 13YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 14
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
(Date:9/17/2014)... 1960s. The typical development phases of trees and stands ... as much as 70 percent. This was the outcome ... Universitt Mnchen based on long-term data from experimental forest ... findings were published recently in Nature Communications . ... topic, with the very survival of large forest ecosystems ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Abnormal properties of cancer protein revealed in fly eyes 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... York University and Rockefeller University have discovered that ... have key roles in gene regulation, can team ... are a recently discovered large class of regulatory, ... in target messenger RNA to regulate their stability ...
... natural process that repairs damage to the human ... has helped establish a method of gene therapy ... disease-causing genes. , The findings are available online ... repair process known as homologous recombination, Dr. Matthew ...
... that allows immune cells known as neutrophils to protect ... at Washington University School of Medicine in St. Louis ... the development of an arthritis-like disorder by making the ... newly identified role for the gene, Foxo3a, may open ...
Cached Biology News:NYU, Rockefeller researchers find complexity of regulation by microRNA genes 2Researchers pioneer new gene therapy technique using natural repair process 2Researchers pioneer new gene therapy technique using natural repair process 3Disabling gene defuses rheumatoid arthritis in mice 2Disabling gene defuses rheumatoid arthritis in mice 3